Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.
Will MAPS Readouts Turn Around The Psychedelic Industry?
It’s been a tough summer for both the cannabis and psychedelics industries. It’s been causing investors a lot of concern. Is there hope that the